Figure 1.
Conventional and DW-MRI of the same lesion from a 55-year-old woman undergoing NACT.
(A)–(C): pretreatment axial (A) and sagittal (B) conventional MR images and diffusion-weighted MR image (C). (D)–(F): preoperative axial (D) and sagittal (E) conventional MR images and diffusion-weighted MR image (F). The red circles in (B)–(F) indicate the largest pretreatment and preoperative lesion as measured in different planes and using different MRI techniques.
Figure 2.
Number of patient enrollment.
Table 1.
Demographics and Clinical Characteristics of Eligible Patients in Prospective Cohort.
Figure 3.
Agreement of tumor sizes, as measured by MRI versus postsurgical pathology.
(A) Bland-Altman plot of tumor size measured by pretreatment MRI examination and postsurgical pathological results; 95% plots are within the limit of agreement (0±10 mm), indicating a good agreement between pretreatment MRI results and postsurgical pathological measurement. (B) Bland-Altman plot of tumor size measured by posttreatment MRI and postsurgical pathology; almost 40% plots are out of the limit of agreement (0±10 mm), which indicates a poor agreement between posttreatment MRI and postsurgical pathology, i.e posttreatment MRI results may not be in place of postsurgical pathological measurement.
Table 2.
Univariate and Multivariate Logistic Analysis of SCC-ag Level and Response to Neoadjuvant Chemotherapy in a Prospective Cohort.
Table 3.
Tumor sizes before and after neoadjuvant chemotherapy with the percent of SCC-ag decease.
Figure 4.
The empirical (A) and smooth (B) AUCs in the validation cohort.
MRI in combination with serum SCC-ag vs. MRI or SCC-ag alone, respectively.
Table 4.
The Accuracy Estimation of NACT Response in an External Validation Cohort.
Table 5.
Apparent diffusion coefficient (ADC) values in the response and non-response patients before and after chemotherapy treatment (mm2⋅s).